HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sture Lindegren Selected Research

Astatine-211

7/2022Estimating the risk for secondary cancer following targeted alpha therapy with astatine-211 intraperitoneal radioimmunotherapy.
1/2021Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer.
11/2019Towards elucidating the radiochemistry of astatine - Behavior in chloroform.
1/2019Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
3/2016Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates.
7/2015Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
2/2015Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.
8/2014Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
7/2014Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status.
10/2007Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sture Lindegren Research Topics

Disease

35Neoplasms (Cancer)
07/2022 - 05/2002
19Ovarian Neoplasms (Ovarian Cancer)
01/2021 - 09/2003
7Carcinoma (Carcinomatosis)
01/2017 - 10/2007
6Ascites
12/2017 - 11/2005
4Body Weight (Weight, Body)
02/2020 - 04/2013
2Ovarian Epithelial Carcinoma
07/2022 - 01/2019
2Residual Neoplasm
02/2020 - 11/2015
2Neoplasm Metastasis (Metastasis)
02/2020 - 08/2014
2Neoplasm Micrometastasis
08/2013 - 09/2003
1Prostatic Neoplasms (Prostate Cancer)
02/2020
1Fatigue
01/2019
1Intestinal Perforation
01/2019
1Breast Neoplasms (Breast Cancer)
10/2016
1Weight Loss (Weight Reduction)
04/2013
1Disease Progression
03/2013

Drug/Important Bio-Agent (IBA)

12Monoclonal AntibodiesIBA
01/2019 - 03/2003
10Astatine-211IBA
07/2022 - 10/2007
7211At-labeled monoclonal antibody MX35IBA
01/2021 - 08/2006
7AntibodiesIBA
01/2021 - 09/2003
5Radioisotopes (Radionuclides)IBA
01/2018 - 07/2011
4AstatineIBA
03/2016 - 09/2003
4Biological ProductsIBA
07/2014 - 03/2003
3Immunoconjugates (Immunoconjugate)IBA
03/2016 - 12/2005
2AntigensIBA
02/2020 - 01/2019
2EpitopesIBA
01/2015 - 09/2003
2Lysine (L-Lysine)FDA Link
12/2011 - 05/2002
1Thorium Dioxide (Thorotrast)IBA
07/2022
1Colloids (Colloid)IBA
07/2022
1Contrast MediaIBA
07/2022
1farletuzumabIBA
01/2021
1Rituximab (Mabthera)FDA Link
01/2021
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
02/2020
1Indicators and Reagents (Reagents)IBA
01/2019
1tanespimycin (17AAG)IBA
10/2016
1TinIBA
03/2016
1Neoplasm Antigens (Tumor Antigens)IBA
01/2015
1Reducing AgentsIBA
08/2014
1HalogensIBA
08/2014
1BR96 monoclonal antibodyIBA
08/2014
1Lutetium-177IBA
08/2014
1Hematoxylin (Haematoxylon)IBA
08/2013
1Eosine Yellowish-(YS) (Eosin)IBA
08/2013
1Lewis Y antigenIBA
04/2013
1procaine isothiocyanate (PRIT)IBA
03/2013
1AvidinIBA
12/2011
1LigandsIBA
07/2011
1N 30IBA
06/2010
1Trastuzumab (Herceptin)FDA Link
10/2007
1Biotin (Vitamin H)FDA Link
09/2003
1poly-d-lysineIBA
09/2003
1SuspensionsIBA
03/2003

Therapy/Procedure

22Radioimmunotherapy
07/2022 - 09/2003
18Therapeutics
07/2022 - 05/2002
9Aftercare (After-Treatment)
02/2020 - 11/2005
4Drug Therapy (Chemotherapy)
07/2022 - 07/2009
2Intravenous Injections
01/2021 - 01/2017
2Catheters
01/2019 - 07/2009
1Castration
02/2020
1Transcutaneous Electric Nerve Stimulation (TENS)
08/2013